Drug intelligence / Profile preview

ethylputreanine nonoate

Development stage: Preclinical
Modality: Small Molecules
Administration: Intratracheal

Overview

Ethylputreanine nonoate is a novel nitric oxide (NO) donor compound, specifically an NO/nucleophile adduct (NONOate). It has been investigated for its hemodynamic effects, particularly its ability to selectively reduce pulmonary vascular resistance. Studies have shown that intratracheal instillation of ethylputreanine nonoate can significantly decrease both pulmonary vascular resistance index (PVRI) and systemic vascular resistance index, suggesting its potential as a treatment for pulmonary hypertension.

Other names: ethylputreanine NONOate

Targets

NO2- (Nitrite)

Beyond the preview

Go deeper on ethylputreanine nonoate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethylputreanine nonoate.

Explore the full profile